8-K: Harrow Inc. Receives Confirmation of IHEEZO Reimbursement Under Medicare Part B

Harrow, Inc. has received confirmation from the Centers for Medicare & Medicaid Services (CMS) that IHEEZO is separately payable in the physician office setting under Medicare Part B.

Summary

• Harrow, Inc. received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 19, 2024.
• The communication confirms that IHEEZO, identified by J-Code 2403, is separately payable in the physician office setting under Medicare Part B.
• This confirmation is based on the inclusion of IHEEZO's J-Code in CMS's April 2024 quarterly drug pricing file.

Sentiment

Score: 8

Explanation: The document conveys positive news regarding reimbursement for IHEEZO, which is a key factor for its commercial success. This is a significant step forward for the company.

Positives

• The confirmation of separate payment for IHEEZO under Medicare Part B is a positive development for Harrow, Inc.
• This allows for reimbursement of IHEEZO when administered in physician offices, potentially increasing its market access and sales.

Future Outlook

The confirmation of IHEEZO's separate payment status under Medicare Part B is expected to positively impact the company's revenue and market penetration.

Industry Context

This announcement is significant for the pharmaceutical industry as it confirms the reimbursement pathway for a specific drug under Medicare Part B, which can influence the adoption and commercial success of the product.

Comparison to Industry Standards

• The process of obtaining separate payment status for drugs under Medicare Part B is a common hurdle for pharmaceutical companies.
• The successful inclusion of IHEEZO's J-Code in the CMS pricing file is a positive outcome, similar to other companies that have successfully navigated this process.
• This outcome is comparable to other pharmaceutical companies that have achieved separate payment status for their products, allowing for broader market access and reimbursement.

Stakeholder Impact

• Shareholders are likely to view this news positively as it increases the potential for revenue generation.
• Physicians will be able to prescribe IHEEZO with the assurance of reimbursement.
• Patients will have increased access to IHEEZO.

Key Dates

Keywords

IHEEZO, Medicare Part B, CMS, Reimbursement, J-Code, Harrow Inc., Drug Pricing, Healthcare